Personalis Past Earnings Performance
Past criteria checks 0/6
Personalis's earnings have been declining at an average annual rate of -37.4%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-37.4%
Earnings growth rate
17.0%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 5.6% |
Return on equity | -83.7% |
Net Margin | -147.4% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Apr 19Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Mar 02Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Dec 18Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
Dec 04Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely
Sep 04Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)
Apr 17The Prognosis For Personalis
Jun 16Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?
Jun 09Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?
Feb 17Personalis: Getting Personal Again
Feb 02Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?
Nov 11Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth
Oct 12We're Hopeful That Personalis (NASDAQ:PSNL) Will Use Its Cash Wisely
Jul 05Personalis: Market-Leading Immuno-Oncology Platform Drives Consistent Long-Term Growth
Jun 21Revenue & Expenses BreakdownBeta
How Personalis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 73 | -108 | 50 | 65 |
30 Sep 23 | 71 | -113 | 54 | 68 |
30 Jun 23 | 67 | -110 | 57 | 66 |
31 Mar 23 | 69 | -114 | 61 | 64 |
31 Dec 22 | 65 | -113 | 64 | 65 |
30 Sep 22 | 69 | -102 | 60 | 63 |
30 Jun 22 | 76 | -94 | 57 | 62 |
31 Mar 22 | 80 | -81 | 53 | 57 |
31 Dec 21 | 85 | -65 | 48 | 49 |
30 Sep 21 | 85 | -58 | 45 | 43 |
30 Jun 21 | 83 | -50 | 41 | 37 |
31 Mar 21 | 80 | -45 | 37 | 32 |
31 Dec 20 | 79 | -41 | 62 | 29 |
30 Sep 20 | 77 | -35 | 29 | 27 |
30 Jun 20 | 74 | -32 | 27 | 26 |
31 Mar 20 | 70 | -29 | 25 | 24 |
31 Dec 19 | 65 | -25 | 22 | 22 |
30 Sep 19 | 60 | -22 | 19 | 19 |
30 Jun 19 | 55 | -19 | 16 | 18 |
31 Mar 19 | 48 | -20 | 13 | 17 |
31 Dec 18 | 38 | -20 | 11 | 14 |
31 Dec 17 | 9 | -24 | 10 | 10 |
Quality Earnings: PSNL is currently unprofitable.
Growing Profit Margin: PSNL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PSNL is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare PSNL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSNL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.5%).
Return on Equity
High ROE: PSNL has a negative Return on Equity (-83.66%), as it is currently unprofitable.